Work

Supplementary Fig. S2 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Fig. S2 - PDF file 123K, Change in Fridericia-corrected QT interval from baseline vs ombrabulin (A) and RPR258063 (B) concentrations as the predictor

DOI: 10.1158/1078-0432.22449276.v1

Authors: Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat-Follet, Jean-Charles Soria

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361819720

Cites:

Cited by:

Related to: 10